A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Feola, Sara et al.·eLife·2022·
RPEP-061202022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The study identified six peptide candidates that successfully controlled tumors in mice.

Key Numbers

How They Did This

The researchers used immunoprecipitation and mass spectrometry to isolate peptides, followed by RNAseq analysis and functional assays to select the best candidates.

Why This Research Matters

This research addresses key challenges in cancer vaccine development, potentially leading to more effective treatments for patients. It sets the stage for future human trials.

What This Study Doesn't Tell Us

The study was conducted in a murine model, and results may not directly translate to humans. Further validation in clinical settings is needed.

Trust & Context

Original Title:
A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
Published In:
eLife, 11 (2022)
Database ID:
RPEP-06120

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06120·https://rethinkpeptides.com/research/RPEP-06120

APA

Feola, Sara; Chiaro, Jacopo; Martins, Beatriz; Russo, Salvatore; Fusciello, Manlio; Ylösmäki, Erkko; Bonini, Chiara; Ruggiero, Eliana; Hamdan, Firas; Feodoroff, Michaela; Antignani, Gabriella; Viitala, Tapani; Pesonen, Sari; Grönholm, Mikaela; Branca, Rui M M; Lehtiö, Janne; Cerullo, Vincenzo. (2022). A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.. eLife, 11. https://doi.org/10.7554/eLife.71156

MLA

Feola, Sara, et al. "A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.." eLife, 2022. https://doi.org/10.7554/eLife.71156

RethinkPeptides

RethinkPeptides Research Database. "A novel immunopeptidomic-based pipeline for the generation o..." RPEP-06120. Retrieved from https://rethinkpeptides.com/research/feola-2022-a-novel-immunopeptidomicbased-pipeline

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.